仑伐替尼联合阿替利珠单抗序贯TACE治疗乙型肝炎合并晚期肝癌患者的效果评价

doi:10.3760/cma.j.issn.1007-1245.2023.11.021

摘要/Abstract

摘要：

目的　探究仑伐替尼联合阿替利珠单抗序贯经导管动脉化疗栓塞术（TACE）在乙型肝炎合并晚期肝癌患者治疗中的应用价值。方法　本研究为随机对照试验。选取2019年1月10日至2022年9月10日聊城市人民医院收治的96例乙型肝炎合并晚期肝癌患者为研究对象，按随机数字表法分为观察组和对照组，各48例。对照组男25例，女23例，年龄（54.52±7.13）岁，给予常规TACE治疗；观察组男28例，女20例，年龄（53.74±6.55）岁，给予仑伐替尼联合阿替利珠单抗序贯TACE治疗。比较两组疾病缓解率、疾病控制率，治疗前后肝功能指标［天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT）、总胆红素（TBIL）］、细胞免疫功能指标［淋巴细胞（CD₃⁺、CD₄⁺、CD₈⁺）、CD₄⁺/CD₈⁺］、浸润转移指标［血管内皮生长因子（VEGF）、磷脂酰肌醇蛋白聚糖-3（GPC-3）］，不良事件发生情况。统计学方法采用t检验、χ²检验、Ridit检验。结果　观察组疾病缓解率、疾病控制率均高于对照组［72.92%（35/48）比52.08%（25/48）、85.42%（41/48）比62.50%（30/48）］（χ²=4.444，P=0.035；χ²=6.544，P=0.010）。治疗后，观察组CD₃⁺、CD₄⁺、CD₄⁺/CD₈⁺分别为（64.28±5.35）%、（33.52±2.81）%、（1.28±0.23），均高于对照组的（58.92±5.13）%、（28.75±2.63）%、（1.03±0.19）；AST、ALT、TBIL、VEGF、GPC-3、CD₈⁺分别为（38.73±8.41）U/L、（47.62±10.39）U/L、（17.95±2.35）µmol/L、（312.58±33.45）ng/L、（10.75±1.98）µg/L、（26.19±2.04）%，均低于对照组的（55.62±7.85）U/L、（67.88±11.55）U/L、（22.46±2.71）µmol/L、（338.74±35.76）ng/L、（12.46±2.05）µg/L、（27.91±2.13）%；差异均有统计学意义（t=15.010、8.587、5.806、10.172、9.035、8.711、3.701、4.156、4.040，均P<0.001）。观察组不良事件总发生率与对照组比较差异无统计学意义［31.25%（15/48）比25.00%（12/48）］（P>0.05）。结论　仑伐替尼联合阿替利珠单抗序贯TACE治疗乙型肝炎合并晚期肝癌患者具有较好的疗效，可有效减轻免疫功能抑制，改善肝功能，缓解病情。

关键词:

肝癌, 乙型肝炎, 仑伐替尼, 阿替利珠单抗, 经肝动脉化疗栓塞术, 免疫功能

Abstract:

Objective　To investigate the value of lenvatinib combined with atezolizumab sequential transhepatic arterial chemoembolization (TACE) in the treatment of patients with hepatitis B complicated with advanced liver cancer. Methods　This study was a randomized controlled trial. A total of 96 patients with hepatitis B complicated with advanced liver cancer admitted to Liaocheng People's Hospital from January 10, 2019 to September 10, 2022 were selected for the study, and were divided into an observation group and a control group according to the random number table method. In the control group, there were 25 males and 23 females, aged (54.52±7.13) years; in the observation group, there were 28 males and 20 females, aged (53.74±6.55) years. The control group was given conventional TACE treatment, and the observation group was given lenvatinib combined with atezolizumab sequential TACE treatment. The disease remission rate, disease control rate, liver function indexes [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBIL)], cellular immune function indexes [lymphocytes (CD₃⁺, CD₄⁺, and CD₈⁺) and CD₄⁺/CD₈⁺], and infiltrative metastasis indexes [vascular endothelial growth factor (VEGF) and glypican-3 (GPC-3)] before and after treatment, and occurrence of adverse events were compared between the two groups. t test, χ² test, and Ridit test were used for statistical analysis. Results　The disease remission rate and disease control rate of the observation group were higher than those of the control group [72.92% (35/48) vs. 52.08% (25/48), 85.42% (41/48) vs. 62.50% (30/48)] (χ²=4.444, P=0.035; χ²=6.544, P=0.010). After treatment, the CD₃⁺, CD₄⁺, CD₄⁺/CD₈⁺ in the observation group were (64.28±5.35)%, (33.52±2.81)%, and (1.28±0.23), which were higher than those in the control group [(58.92±5.13)%, (28.75±2.63)%, and (1.03±0.19)]; the AST, ALT, TBIL, VEGF, GPC-3, and CD₈⁺ were (38.73±8.41) U/L, (47.62±10.39) U/L, (17.95±2.35) µmol/L, (312.58±33.45) ng/L, (10.75±1.98) µg/L, and (26.19±2.04)%, which were lower than those in the control group [(55.62±7.85) U/L,(67.88±11.55) U/L, (22.46±2.71) µmol/L, (338.74±35.76) ng/L, (12.46±2.05) µg/L, and (27.91±2.13)%]; the differences were statistically significant (t=15.010, 8.587, 5.806, 10.172, 9.035, 8.711, 3.701, 4.156, and 4.040; all P<0.001). There was no statistically significant difference in the total incidence of adverse events between the observation group and the control group [31.25% (15/48) vs. 25.00% (12/48)] (P>0.05). Conclusion　Lenvatinib combined with atezolizumab sequential TACE has better clinical effect in the treatment of patients with hepatitis B complicated with advanced liver cancer, which can effectively reduce the immune suppression, improve the liver function, and alleviate the disease.

Key words:

Liver cancer, Hepatitis B, Lenvatinib, Atezolizumab, TACE, Immune function

刘春华刘玲陶昌明贺玉凯.

仑伐替尼联合阿替利珠单抗序贯TACE治疗乙型肝炎合并晚期肝癌患者的效果评价 [J]. 国际医药卫生导报, 2023, 29(11): 1573-1578.

Liu Chunhua, Liu Ling, Tao Changming, He Yukai.

Efficacy evaluation of lenvatinib combined with atezolizumab sequential TACE in the treatment of patients with hepatitis B complicated with advanced liver cancer [J]. International Medicine and Health Guidance News, 2023, 29(11): 1573-1578.

参考文献

[1] 刘潇霞,乔良,罗玉英,等. 2018年四川省以医院登记为基础的恶性肿瘤发病情况分析[J]. 中国肿瘤,2021,30(6):429-436. DOI:10.11735/j.issn.1004-0242.2021.06.A005.
[2] 唐琳琳,李洪英,刘文山,等. 人参皂苷Rg3抗肝癌作用研究进展[J]. 国际医药卫生导报,2022,28(7):912-916. DOI:10.3760/cma.j.issn.1007-1245.2022.07.006.
[3] 张仲良,李静喆,何玉奇,等.放射性125I粒子植入联合肝动脉化疗栓塞术治疗中晚期肝癌的临床疗效评价[J].国际放射医学核医学杂志,2022,46(9):544-549. DOI:10.3760/cma.j.cn121381-202205004-00217.
[4] 张萌,沙金平,高毅,等.仑伐替尼联合肝癌介入化疗栓塞术在中晚期肝癌患者中的应用[J].中西医结合肝病杂志,2022,32(3):275-276. DOI:10.3969/j.issn.1005-0264. 2022.03.024.
[5] 姚博文,向俊西,郑鑫,等.阿替利珠单克隆抗体联合贝伐珠单克隆抗体治疗初始临界可切除中晚期肝癌的临床疗效[J].中华消化外科杂志,2022,21(2):303-306. DOI:10.3760/cma.j.cn115610-20220120-00045.
[6] Shrestha B, Dunn L. The declaration of helsinki on medical research involving human subjects: a review of seventh revision[J]. J Nepal Health Res Counc, 2020, 17(4): 548-552. DOI:10.33314/jnhrc.v17i4.1042.
[7] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华消化外科杂志,2017,16(7):635-647. DOI:10.3760/cma.j.issn.1673-9752.2017. 07.001.
[8] 中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J].介入放射学杂志,2018,27(12):1117-1126. DOI:10.3969/j.issn.1008- 794X.2018.12.001.
[9] 靳宏虎,赵长应,张桢,等.两种实体瘤疗效评价标准对肝细胞癌患者系统化疗效果评价的比较[J].中华肝胆外科杂志,2019,25(6):411-414. DOI:10.3760/cma.j.issn.1007-8118. 2019.06.003.
[10] 周泽文,刘颖春,向邦德,等.原发性肝癌的全球展望:流行情况、危险因素和人群归因分值[J].中国癌症防治杂志,2021,13(1):14-21 .DOI:10.3969/j.issn.1674-5671.2021. 01.03.
[11] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604. DOI:10.1038/s41575-019-0186-y.Epub 2019 Aug 22.
[12] Li KY, Zhang SM, Shi CX, et al. Effect of prophylactic transcatheter arterial chemoembolization on hepatocellular carcinoma with microvascular invasion after R0 resection.a case-control study[J].Sao Paulo Med J, 2020, 138(1): 60-63. DOI:10.1590/1516-3180.2019.0042.R1.05072019.
[13] 朱方,魏娟,赵慧慧,等. 仑伐替尼和卡瑞利珠单抗联合TACE术治疗晚期或不可切除肝细胞癌临床疗效[J]. 东南大学学报(医学版),2022,41(4):557-561. DOI:10.3969/j.issn.1671-6264.2022.04.016.
[14] 丁晓鹏,帖君,余嘉豪,等. 经肝动脉化疗栓塞术联合抗血管生成药基础上使用程序性死亡受体1抑制剂治疗中晚期肝细胞癌的有效性和安全性分析[J]. 临床肝胆病杂志,2022,38(5):1086-1091. DOI:10.3969/j.issn.1001-5256. 2022.05.021.
[15] 张晓赟,朱心睿,彭伟,等. 经肝动脉化疗栓塞+仑伐替尼+PD-1单抗在中晚期不可切除肝癌转化切除中的安全性和有效性的前瞻性队列研究:初步报告[J]. 中国普外基础与临床杂志,2022,29(1):39-45. DOI:10.7507/1007-9424. 202111006.
[16] 韩孟奎,李晋,杨小华. 肝细胞癌肿瘤免疫微环境中T淋巴细胞的功能与调控机制[J]. 临床肝胆病杂志,2022,38(11):2621-2626. DOI:10.3969/j.issn.1001-5256.2022.11.037.
[17] 刘慧敏,刘晓利,王欣惠,等. 原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义[J]. 实用肝脏病杂志,2022,25(2):255-258. DOI:10.3969/j.issn.1672-5069.2022.02.026.
[18] 陈庆元,朱杰军,何文丽. 支气管肺炎患儿血清LDH3、CRP及免疫功能变化的临床意义[J]. 标记免疫分析与临床,2020,27(8):1390-1394. DOI:10.11748/bjmy.issn.1006- 1703.2020.08.026.
[19] 宋琛,孙亚洲,李强,等. CD200与CD4+CD25+CD127 low Treg在强直性脊柱炎中的意义[J]. 中国免疫学杂志,2020,36(2):215-221. DOI:10.3969/j.issn.1000- 484X.2020.02.016.
[20] 孙玲,谢兴元,周杜鹃,等.难治性肾病综合征儿童血清中CD3+、CD4+、CD8+、CD4+/CD8+水平的变化及临床意义[J].国际医药卫生导报,2021,27(17):2676-2679.DOI:10.3760/cma.j.issn.1007-1245.2021.17.009.
[21] 中国临床肿瘤学会血管靶向治疗专家委员会,中国临床肿瘤学会非小细胞肺癌专家委员会,中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版)[J]. 中华肿瘤杂志,2020,42(12):1063-1077. DOI:10.3760/cma.j.cn112152-20200918-00836.
[22] 李贻弘,张宏,熊首先. miR-125a下调血管因子VEGF抑制肝癌细胞的侵袭、增殖、迁移及周期S期[J]. 河北医药,2019,41(16):2405-2410. DOI:10.3969/j.issn.1002-7386. 2019.16.001.
[23] 刘杜先,张杰东,方媛,等. GPC-3、CD147、CD10、CD138在肝细胞肝癌中的表达及临床意义[J]. 国际检验医学杂志,2020,41(7):826-830,835. DOI:10.3969/j.issn.1673-4130.2020.07.014.
[24] 王子柯,段斯亮,李海兰,等. GPC-3与AFP单项及联合检测对HCC诊断价值的Meta分析[J]. 广西科技大学学报,2022,33(2):116-125. DOI:10.16375/j.cnki.cn45-1395/t.2022.02.017.